Carcinogenicity comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-06-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | GW501516; GW-1516; endurobol | GW501516 is the research code |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator |
| Molecular formula | C21H18F3NO3S2 | Established chemical formula |
| Molar mass | 453.5 g/mol | Calculated from the formula |
| Regulatory status | Prohibited in sport; not approved as medicine | Status varies by country |
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
== Pharmacology == The OATPs play a role in the transport of some classes of drugs across the cell membrane, particularly in the liver and kidney. In the liver, OATPs are expressed on the basolateral membrane of hepatocytes, transporting compounds into the hepatocyte for biotransformation. A number of drug-drug interactions have been associated with the OATPs, affecting the pharmacokinetics and pharmacodynamics of drugs. This is most commonly where one drug inhibits the transport of another drug into the hepatocyte, so that it is retained longer in the body (i.e. increased plasma half-life). The OATPs most associated with these interactions are OATP1B1, OATP1B3 and OATP2B1, which are all present on the hepatocyte basolateral (sinusoidal) membrane. OATP1B1 and OATP1B3 are known to play an important role in hepatic drug disposition. These OATPs contribute towards first step of hepatic accumulation and can influence the disposition of drug via hepatic route. The most clinically relevant interactions have been associated with the lipid lowering drugs statins, which led to the removal of cerivastatin from the market in 2002. Single nucleotide polymorphisms (SNPs) are also associated with the OATPs; particularly OATP1B1. Many modulators of OATP function have been identified based on in vitro research in OATP-transfected cell lines. Both OATP activation and inhibition has been observed and an in silico model for structure-based identification of OATP modulation was developed.
The death of Roosevelt, the end of the need for a wartime alliance against Germany, and the determination by American war planners that Soviet assistance in Manchuria would not be needed to defeat Japan, meant that the major barriers to disengaging with the Soviets had been eliminated. Following the Allied victory in May, the Soviets effectively occupied Eastern Europe, while the US had much of Western Europe. In occupied Germany, the US and the Soviet Union established zones of occupation and a loose framework for four-power control with the ailing French and British.
Signs and Symptoms: 4 Phases: Premycotic Phase: Scale-like red rash on areas of the skin that are not exposed to the sun. Patch Phase: An itchy, thin rash Plaque Phase: Raised bumps or lesions present on the skin Tumor Phase: Tumors begin to form on the skin near or under the lesions. 4 Stages Diagnosis: Physical exam to check for lesions Peripheral blood smear Use a microscope to count the number of blood cells and look at their shape. Skin biopsy Checks for signs of cancer Immunophenotyping Flow cytometry T-cell receptor gene rearrangement test Liver Function Test HIV test X-ray, CT scan, and PET scan To determine if the lymphoma is metastatic Treatments: Chemotherapy Radiation Drug Therapy Photodynamic Therapy Biologic Therapy using Interferon Targeted Therapy UV Radiation Therapy Clinical Trials being pursued Stem cell transplant combined with chemoradiation Clinical trials being pursued
=== Other FDA measures === One exception occurred during the 2010 Swine Flu Epidemic when the FDA authorized expired Tamiflu based on SLEP Data. The US FDA is able to extend the shelf life of drugs throughout national, state, local, tribal, and territorial stockpiles through two legal means: by issuing an Emergency Use Authorization on using a drug past its expiration date (which is legally an unapproved use of a drug), or by a "expiration dating extension authority" established by the Pandemic and All-Hazards Preparedness Reauthorization Act of 2013 (PAHPRA). The PAHPRA authority only applies to so-called medical countermeasures (MCMs), which are drugs and other tools used to counter CBRN emergencies. Furthermore, FDA can choose to not take enforcement action against use of a drug past its expiration date using its enforcement discretion, but this kind of discretion is not covered by Public Readiness and Emergency Preparedness Act liability protections. The FDA has, using these three measures, provided shelf life extensions on Covid-19 vaccines, Covid-19 antibody therapeutics, Covid-19 in vitro diagnostics, flu antivirals (Tamiflu, Relenza), doxycycline, the Jynneos Mpox vaccine (one single lot), nerve agent autoinjectors, and potassium iodide.
Morpholino nucleic acids replace the sugar with a morpholine component, and the phosphate with a phosphorodiamidate component. Miravirsen is an antisense drug candidate that incorporates both locked nucleic acid sugar components and phosphorothioate groups.
Sources: en.wikipedia.org
Hyaluronic acid is one of the most common materials used for injectable filler procedures due to its natural presence in vertebrates. Its inherent biocompatibility and biodegradability makes it particularly well suited for these applications, contributing to its widespread use in aesthetic and medical treatments. The chemical structure of hyaluronic acid is made up of repeating disaccharide units that consist of N-acetyl-D-glucosamine and D-glucuronic acid. Crosslinking Mechanisms in Injectable Fillers Crosslinking mechanisms determine the mechanical stability, degradation behavior, prolonged in vivo retention time, and in situ gelation properties of the injectable filler material. Hydrogels used as injectable fillers may be formed through physical (non-covalent) interactions or chemical (covalent) crosslinking, with chemical crosslinking generally providing greater stability and tunability. In collagen-based fillers, crosslinking methods such as glutaraldehyde treatment have been used to enhance integration, while synthetic fillers like poly(methyl methacrylate) rely on particulate scaffolds that induce fibrotic tissue formation rather than on degradable networks. Among chemical approaches, enzymatic crosslinking has gained prominence for its ability to proceed under physiological conditions without toxic catalysts or external stimuli such as ultraviolet light. Common enzymatic crosslinking mechanisms include horseradish peroxidase (HRP), tyrosinase, and transglutaminase.
=== Disorders of osteoid mineralization === Defective mineralization of osteoid leads to several important clinical conditions characterized by accumulation of unmineralized matrix. Rickets: Occurs in children when defective mineralization affects the growth plate and osteoid. The condition results from calcium or phosphate deficiency, either isolated or secondary to vitamin D deficiency. In rickets, the mineralization defect leads to accumulation of osteoid in bone tissue below the growth plate, resulting in weak bones and deformities. Osteomalacia: The adult equivalent of rickets, osteomalacia is characterized by softened bones due to impaired mineralization of osteoid. Vitamin D deficiency is the most common cause, though calcium or phosphate deficiency can also result in osteomalacia. The condition manifests as bone pain, muscle weakness, and increased fracture risk. Histomorphometric characteristics of osteomalacia include:
=== Japan === In 2006 the United States, France, and Japan signed an "arrangement" to research and develop sodium-cooled fast reactors in support of the Global Nuclear Energy Partnership. In 2007 the Japanese government selected Mitsubishi Heavy Industries as the "core company in FBR development in Japan". Shortly thereafter, Mitsubishi FBR Systems was launched to develop and eventually sell FBR technology. A 2024 technical review by Mitsubishi Heavy Industries described the revised Japanese roadmap: conceptual design and research on a demonstration sodium-cooled fast reactor were planned for fiscal 2024–2028, with a decision on basic design and licensing around fiscal 2028. MHI had been selected as the project's lead company in July 2023.
== Modern cultivation == Seed yield varies depending on cultivars, mode of cultivation, and growing conditions by geographic region. For example, commercial fields in Argentina and Colombia vary in yield range from 450 to 1,250 kg/ha (400 to 1,120 lb/acre). A small-scale study with three cultivars grown in the inter-Andean valleys of Ecuador produced yields up to 2,300 kg/ha (2,100 lb/acre), indicating that favorable growing environment and cultivar interacted to produce such high yields.[20] Genotype has a larger effect on yield than on protein content, oil content, fatty acid composition, or phenolic compounds, whereas high temperature reduces oil content and degree of unsaturation, and raises protein content.
Hims & Hers Health, Inc., doing business as hims, is an American telehealth company headquartered in San Francisco. It provides prescription medications, over-the-counter medications, and personal care products through a direct-to-consumer subscription model.
Sources: en.wikipedia.org
No. Cardarine is GW501516, a PPARδ agonist, while SARMs act on androgen receptors. The two classes are often grouped in informal discussions despite different mechanisms.
No. It has no approved medical indication in any country. Regulatory agencies have not cleared it for treatment or prevention of any condition.
Early clinical work stopped after rodent carcinogenicity findings. Those animal results raised concerns about long-term human risk, although direct human evidence is lacking. The human relevance of the tumors remains an open scientific question.
It binds and activates PPARδ, a nuclear receptor that influences gene expression related to fatty acid metabolism and energy balance. This mechanism has been studied mainly in animals and cell models, not established as a safe human therapy.